Women who breastfed their infants for a longer duration appeared to have a lower risk of diabetes compared with women who did not breastfeed, according to an observational study spanning three decades.
Women who undergo a hysterectomy with bilateral ovarian conservation appear to have an elevated risk of cardiovascular (CV) and metabolic disease, particularly those who undergo the procedure at age 35 or younger, a recent study found.
Severe postnatal depression (PND), especially if persisting up to 11 years after birth, raises the risk of adverse child outcomes such as child behavioural and developmental disturbances, according to a recent study.
A double intravenous vasopressor automated system appears to be more effective than manual vasopressor bolus administration at controlling maternal blood pressure following spinal anaesthesia during caesarean delivery, a new Singapore study has shown.
A family physician (GP)-led, community screening programme helped reduce the incidence of hip fracture in older women, highlighting the important role played by GPs in reducing the morbidity associated with hip fractures in this population, the UK-based SCOOP* trial revealed.
Maternal diet appears to influence health outcomes of the offspring, suggests a recent Singapore study, which shows that higher diet quality during pregnancy is correlated with longer birth length and lower neonatal adiposity.
The use of an oestradiol patch in addition to oral intermittent micronized progesterone for 1 year helped prevent the development of depressive symptoms in women going through menopause, particularly those in the early stages of the menopause transition, a recent study found.
Cannabis use during pregnancy increases the risk of maternal anaemia, and causes several adverse outcomes in infants like low birth weight (LBW), and increased neonatal intensive care unit (NICU) admissions, show findings of a systematic review and meta-analysis.
Estrogen receptor α (ESR1) mutations Y537S and D538G are associated with reduced overall survival (OS) in patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer, according to findings of a secondary analysis of the BOLERO-2* clinical trial.